IMMUNIC Business Summary

Immunic, Inc. (IMUX) is a late-stage clinical biotechnology company transitioning into a commercial-stage entity, primarily focused on developing oral, small-molecule therapies for chronic inflammatory and autoimmune diseases. The company’s business model centers on the clinical advancement and eventual commercialization or licensing of its immunology pipeline, with revenue currently generated through interest income and strategic private placements rather than product sales. Its primary business segments target neurologic and gastrointestinal disorders, led by its flagship asset, vidofludimus calcium (IMU-838), which is undergoing Phase 3 ENSURE trials for relapsing multiple sclerosis (RMS) and has shown neuroprotective potential in Phase 2 CALLIPER trials for progressive MS. Other key pipeline assets include IMU-856 for intestinal barrier restoration and IMU-935, a RORγt inverse agonist. Immunic competes directly with small-to-mid-cap biotechs such as Immix Biopharma (IMMX), Protara Therapeutics (TARA), Aldeyra Therapeutics (ALDX), and Atea Pharmaceuticals (AVIR), positioning itself as a high-upside specialist in oral MS therapies with a projected New Drug Application (NDA) submission in mid-2027. Founded by Dr. Daniel Vitt, Dr. Hella Kohlhof, and Dr. Andreas Mühler, Immunic is currently undergoing a strategic leadership pivot to support its commercial evolution. As of February 2026, co-founder Dr. Daniel Vitt is transitioning from Chief Executive Officer to a senior scientific executive role, with an active search underway for a successor possessing deep commercial expertise in the MS market. The executive team includes Jason Tardio (President and COO), a veteran of Novartis and Biogen, and Glenn Whaley (CFO), who brings over 30 years of pharmaceutical finance experience. Following a landmark $400 million private placement in February 2026, Simona Skerjanec, a former Roche executive, was appointed Interim Chairperson of the Board. The company is backed by a high-pedigree investor syndicate led by BVF Partners L.P., with participation from institutional heavyweights including OrbiMed, RA Capital Management, Avidity Partners, and Janus Henderson Investors.